Literature DB >> 25102011

Improved retroviral episome transfer of transcription factors enables sustained cell fate modification.

J W Schott1, D Hoffmann1, T Maetzig1, F-J Müller2, D Steinemann3, D Zychlinski1, T Cantz4, C Baum1, A Schambach5.   

Abstract

Retroviral vectors are versatile gene transfer vehicles widely used in basic research and gene therapy. Mutation of retroviral integrase converts these vectors into transient, integration-deficient gene delivery vehicles associated with a high degree of biosafety. We explored the option to use integration-deficient retroviral vectors to achieve transient ectopic expression of transcription factors, which is considered an important tool for induced cell fate conversion. Stepwise optimization of the retroviral episome transfer as exemplified for the transcription factor Oct4 enabled to improve both expression magnitude and endurance. Long terminal repeat-driven γ-retroviral vectors were identified as the most suitable vector architecture. Episomal expression was enhanced by epigenetic modifiers, and Oct4 activity was increased following fusion to a minimal transactivation motif of herpes simplex virus VP16. Based on kinetic analyses, we identified optimal time intervals for repeated vector administration and established prolonged expression windows of choice. Providing proof-of-concept, episomal transfer of Oct4 was potent to mediate conversion of human fibroblasts stably expressing Klf4, Sox2 and c-Myc into induced pluripotent stem cells, which were mainly free of residual Oct4 vector integration. This study provides evidence for suitability of retroviral episome transfer of transcription factors for cell fate conversion, allowing the generation of distinct patient- or disease-specific cell types.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25102011     DOI: 10.1038/gt.2014.69

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  5 in total

1.  Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells.

Authors:  D Hoffmann; J W Schott; F K Geis; L Lange; F-J Müller; D Lenz; D Zychlinski; D Steinemann; M Morgan; T Moritz; A Schambach
Journal:  Gene Ther       Date:  2017-04-20       Impact factor: 5.250

Review 2.  The retroviral vector family: something for everyone.

Authors:  Carina Elsner; Jens Bohne
Journal:  Virus Genes       Date:  2017-07-31       Impact factor: 2.332

Review 3.  The interplay of post-translational modification and gene therapy.

Authors:  Victor Chukwudi Osamor; Shalom N Chinedu; Dominic E Azuh; Emeka Joshua Iweala; Olubanke Olujoke Ogunlana
Journal:  Drug Des Devel Ther       Date:  2016-02-29       Impact factor: 4.162

4.  Enhancement of mouse hematopoietic stem/progenitor cell function via transient gene delivery using integration-deficient lentiviral vectors.

Authors:  Maria E Alonso-Ferrero; Niek P van Til; Kerol Bartolovic; Márcia F Mata; Gerard Wagemaker; Dale Moulding; David A Williams; Christine Kinnon; Simon N Waddington; Michael D Milsom; Steven J Howe
Journal:  Exp Hematol       Date:  2017-09-11       Impact factor: 3.084

5.  Genetic Correction of IL-10RB Deficiency Reconstitutes Anti-Inflammatory Regulation in iPSC-Derived Macrophages.

Authors:  Dirk Hoffmann; Johanna Sens; Sebastian Brennig; Daniel Brand; Friederike Philipp; Philippe Vollmer Barbosa; Johannes Kuehle; Doris Steinemann; Daniela Lenz; Theresa Buchegger; Michael Morgan; Christine S Falk; Christoph Klein; Nico Lachmann; Axel Schambach
Journal:  J Pers Med       Date:  2021-03-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.